Edwards Lifesciences Corporation (NYSE: EW) has been recovering from recent weakness, supported by steady procedure growth and high profitability. Shares trade near $76, as investors regain confidence in the company’s strong execution and continued leadership in heart valve therapies.
Recently, Edwards reported solid third-quarter results that reflected ongoing demand for its transcatheter aortic valve products and expanding adoption of its mitral and tricuspid repair systems. The company has also seen continued uptake of its Pascal Precision system, a minimally invasive therapy approved by the FDA in 2022 for treating degenerative mitral regurgitation. These developments highlight Edwards’ innovation strength and reinforce its position in the fast-growing structural heart market.
This article explores where Wall Street analysts think Edwards could trade by 2027. We have gathered consensus price targets and valuation model data to outline the stock’s potential path. These figures reflect current analyst expectations and are not TIKR’s own predictions.
Find out what a stock’s really worth in under 60 seconds with TIKR’s new Valuation Model (It’s free) >>>
Analyst Price Targets Suggest Modest Upside
Edwards trades near $76/share, while the average analyst price target is about $87/share, implying roughly 15% upside. Forecasts remain relatively close together, showing cautious optimism around growth expectations:
- High estimate: ~$100/share
- Low estimate: ~$72/share
- Ratings: 13 Buys, 4 Outperforms, 15 Holds, 1 Sell
This points to modest upside rather than a breakout move. For investors, analysts believe Edwards’ consistent execution and innovation could support further gains if hospital procedure volumes keep improving and new product launches drive adoption in structural heart therapies.
Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free) >>>
Edwards Lifesciences: Growth Outlook and Valuation
The company’s fundamentals remain strong and steady:
- Revenue projected to grow around 9–10% annually through 2027
- Operating margins expected near 28%
- Shares trade at roughly 29x forward earnings, close to the sector average
- Based on analysts’ average estimates, TIKR’s Guided Valuation Model using a 29.5x forward P/E suggests ~$102/share by 2027
- That implies around 34% total upside, or roughly 14% annualized returns
For investors, this means Edwards offers a balanced mix of quality and growth. The company’s durable margins, strong cash generation, and leadership in transcatheter valve technologies give it a long runway for compounding returns. Upside potential looks realistic if new therapies scale successfully and market share gains continue in emerging categories like mitral and tricuspid interventions.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
What’s Driving the Optimism?
Edwards remains one of the most dominant players in structural heart therapies. Its transcatheter aortic valve (TAVR) business continues to expand globally, supported by aging populations and broader hospital adoption. The company’s innovation pipeline in mitral and tricuspid therapies, including Pascal Precision and upcoming next-generation devices, offers new growth opportunities that could extend its leadership in minimally invasive care.
Management’s focus on innovation, clinical leadership, and disciplined capital allocation reinforces Edwards’ competitive edge. For investors, these strengths suggest the company can maintain its growth trajectory and compound earnings steadily as new therapies reach more patients.
Bear Case: Growth Normalization and Competition
Even with these positives, Edwards’ valuation already assumes steady growth and strong execution. If procedure volumes slow or hospitals pull back on equipment spending, earnings progress could lose momentum.
Competition from Medtronic and Abbott also poses a challenge, especially as both push deeper into transcatheter therapies. For investors, the key risk is that Edwards’ premium status could face pressure if rivals gain share or pricing weakens in core markets.
Outlook for 2027: What Could Edwards Be Worth?
Based on analysts’ average estimates, TIKR’s Guided Valuation Model suggests Edwards could trade near $102/share by 2027. That would represent about 34% upside from current levels, or roughly 14% annualized returns.
While this points to healthy potential gains, it already assumes steady execution and margin consistency. To deliver stronger upside, Edwards would need faster adoption of its next-generation therapies and continued share gains in emerging markets.
For investors, Edwards stands out as a reliable long-term compounder. It may not deliver explosive growth, but its innovation pipeline and market leadership provide a solid foundation for consistent returns through 2027.
Find out what your favorite stocks are really worth (Free with TIKR) >>>
AI Compounders With Massive Upside That Wall Street Is Overlooking
Everyone wants to cash in on AI. But while the crowd chases the obvious names benefiting from AI like NVIDIA, AMD, or Taiwan Semiconductor, the real opportunity may lie on the AI application layer where a handful of compounders are quietly embedding AI into products people already use every day.
TIKR just released a new free report on 5 undervalued compounders that analysts believe could deliver years of outperformance as AI adoption accelerates.
Inside the report, you’ll find:
- Businesses already turning AI into revenue and earnings growth
- Stocks trading below fair value despite strong analyst forecasts
- Unique picks most investors haven’t even considered
If you want to catch the next wave of AI winners, this report is a must-read.
Click here to sign up for TIKR and get your free copy of TIKR’s 5 AI Compounders report today.
